Data provider Accession Acronym URL
The PROCARDIS programme to identify susceptibility loci in precocious CAD, was initiated in October 1998 as a collaboration between the universities of Oxford and Munster, the Karolinska Institute, the Mario Negri Institute, Oxagen (a biotechnology company), and AstraZeneca (the pharmaceutical company). This consortium received support from a Concerted Action award of the 5th Framework Programme and 6th Framework Programme. We have a collection of 3,000 affected sibling pairs (ASPs) and families with precocious CAD (onset before the age of 65 years) and have applied genome-wide linkage mapping techniques by typing SNPs spaced throughout the genome. Thus the PROCARDIS programme has been designed to allow mapping of novel CAD susceptibility genes without being limited by current knowledge of disease mechanisms.

This data provider is associated with 1 studies:

Study Accessionsort ascending Title
EGAS00000000055 Procardis study on novel susceptibility genes for coronary artery disease (CAD)